

Michael A Arnold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11052189/publications.pdf>

Version: 2024-02-01

61
papers

2,395
citations

279798

23
h-index

206112

48
g-index

61
all docs

61
docs citations

61
times ranked

4612
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e696-e702.	4.4	1
2	Is the appendix a good organ to diagnose total colonic aganglionosis?. <i>Pediatric Surgery International</i> , 2022, 38, 25-30.	1.4	2
3	Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor. <i>Cancer</i> , 2022, 128, 373-382.	4.1	11
4	Short NK- and Naïve T-Cell Telomere Length Is Associated with Thyroid Cancer in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 453-460.	2.5	3
5	Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. <i>European Journal of Cancer</i> , 2022, 168, 56-64.	2.8	8
6	Selective Immunoreactivity for WT1 Carboxy-Terminus Distinguishes Desmoplastic Small Round Cell Tumor From its Histologic Mimics. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 504-510.	1.0	1
7	Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Cancer</i> , 2021, 127, 946-956.	4.1	18
8	Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28914.	1.5	9
9	MYOD1 as a prognostic indicator in rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29085.	1.5	5
10	Polygenic Risk Score Improves Risk Stratification and Prediction of Subsequent Thyroid Cancer after Childhood Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2096-2104.	2.5	11
11	Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. <i>Journal of Clinical Oncology</i> , 2021, 39, 3012-3021.	1.6	9
12	Challenges in the Diagnosis of Pediatric Spindle Cell/Sclerosing Rhabdomyosarcoma. <i>Surgical Pathology Clinics</i> , 2020, 13, 729-738.	1.7	6
13	Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1238-1245.	2.8	9
14	Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study. <i>JCO Precision Oncology</i> , 2020, 4, 926-936.	3.0	9
15	Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. <i>PLoS ONE</i> , 2020, 15, e0228887.	2.5	18
16	Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2120-2130.	1.6	35
17	Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. <i>Journal of Clinical Oncology</i> , 2019, 37, 3310-3319.	1.6	67
18	Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use. <i>JAMA Pediatrics</i> , 2019, 173, 1171.	6.2	40

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A for Subsequent Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2042-2045.e8.	0.7	18
20	Cytoplasmic Fibrillar Aggregates in Gallbladder Epithelium Are a Frequent Mimic of Cystoisospora in Pediatric Cholecystectomy Specimens. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1259-1264.	2.5	4
21	Infra-anastomotic Innervation of Residual Aganglionic Distal Rectum After Pull-through Surgery for Hirschsprung Disease. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 420-430.	1.0	3
22	Multifocal Appendiceal Carcinoid Tumor in an Adolescent: A Case Report and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 568-570.	0.6	0
23	Remodeling of Rectal Innervation After Pullthrough Surgery for Hirschsprung Disease: Relevance to Criteria for the Determination of Retained Transition Zone. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 292-303.	1.0	14
24	Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 417-419.	2.5	7
25	Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation sensitivity syndrome genes: A report from the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10028-10028.	1.6	1
26	Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 10060-10060.	1.6	0
27	Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 10053-10053.	1.6	0
28	Comparison of Radiation Dose Reconstruction Methods to Investigate Late Adverse Effects of Radiotherapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. <i>Radiation Research</i> , 2019, 193, 95.	1.5	4
29	IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. <i>JCI Insight</i> , 2018, 3, .	5.0	59
30	Comprehensive molecular characterization of pediatric treatment-induced glioblastoma: Germline DNA repair defects as a potential etiology.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10573-10573.	1.6	1
31	Subsequent malignant neoplasms (SMNs) among non-irradiated survivors of childhood cancer treated with chemotherapy in the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10509-10509.	1.6	0
32	Molecular diagnostics in the management of rhabdomyosarcoma. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 189-194.	3.1	48
33	Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 814.	7.4	169
34	If You Are Not on Social Media, Here's What You're Missing! #DoTheThing. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1567-1576.	2.5	24
35	Crospovidone and Microcrystalline Cellulose. <i>American Journal of Surgical Pathology</i> , 2017, 41, 564-569.	3.7	16
36	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26645.	1.5	82

#	ARTICLE	IF	CITATIONS
37	Human papillomavirus (HPV)-associated malignancies as subsequent malignant neoplasms (SMN) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2017, 35, 10566-10566.	1.6	1
38	Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget, 2017, 8, 82037-82048.	1.8	41
39	PNR-19CRIBIFORM NEUROEPITHELIAL TUMOR (CRINET) ARISING FROM THE LATERAL VENTRICLE: A CASE OF RARITY AND FAVORABLE OUTCOME. Neuro-Oncology, 2016, 18, iii10.3-iii10.	1.2	0
40	Characterization of MHC Class I and Î²2-microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. Pediatric Blood and Cancer, 2016, 63, 618-626.	1.5	12
41	Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases. Case Reports in Oncology, 2016, 9, 447-453.	0.7	0
42	A Strategy for Helicobacter Immunohistochemistry Utilization in Pediatric Practice. American Journal of Clinical Pathology, 2016, 146, 611-617.	0.7	2
43	Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 634-639.	1.5	53
44	Changing patterns of subsequent malignancies in the Childhood Cancer Survivor Study cohort.. Journal of Clinical Oncology, 2016, 34, 10503-10503.	1.6	0
45	Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane [®]) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2015, 62, 1214-1221.	1.5	29
46	The College of American Pathologists Guidelines for Whole Slide Imaging Validation are Feasible for Pediatric Pathology: A Pediatric Pathology Practice Experience. Pediatric and Developmental Pathology, 2015, 18, 109-116.	1.0	27
47	The Bethesda System for Reporting Thyroid Cytopathology is Applicable to Frozen Section Diagnosis in Children. Pediatric and Developmental Pathology, 2015, 18, 139-145.	1.0	3
48	What's new in small round blue cell sarcomas?. Diagnostic Histopathology, 2015, 21, 425-431.	0.4	0
49	Colesevelam and Colestipol. American Journal of Surgical Pathology, 2014, 38, 1530-1537.	3.7	36
50	Diagnostic Pitfalls of Differentiating Desmoplastic Small Round Cell Tumor (DSRCT) From Wilms Tumor (WT). American Journal of Surgical Pathology, 2014, 38, 1220-1226.	3.7	56
51	Phagocytized Neutrophil Fragments in the Bone Marrow: A Phenomenon Most Commonly Associated with Hodgkin Lymphoma. ISRN Hematology, 2014, 2014, 1-5.	1.6	4
52	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy - Oncolytics, 2014, 1, 14010.	4.4	33
53	Cribiform Neuroepithelial Tumor Arising in the Lateral Ventricle. Pediatric and Developmental Pathology, 2013, 16, 301-307.	1.0	19
54	A unique pattern of INI1 immunohistochemistry distinguishes synovial sarcoma from its histologic mimics. Human Pathology, 2013, 44, 881-887.	2.0	48

#	ARTICLE	IF	CITATIONS
55	Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. <i>Blood</i> , 2009, 114, 2476-2488.	1.4	68
56	The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. <i>Blood</i> , 2008, 111, 4532-4541.	1.4	59
57	Regulation of HDAC9 Gene Expression by MEF2 Establishes a Negative-Feedback Loop in the Transcriptional Circuitry of Muscle Differentiation. <i>Molecular and Cellular Biology</i> , 2007, 27, 518-525.	2.3	124
58	MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development. <i>Developmental Cell</i> , 2007, 12, 377-389.	7.0	401
59	Regulation of Skeletal Muscle Sarcomere Integrity and Postnatal Muscle Function by <i>Mef2c</i> . <i>Molecular and Cellular Biology</i> , 2007, 27, 8143-8151.	2.3	190
60	Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. <i>Journal of Clinical Investigation</i> , 2007, 117, 2459-2467.	8.2	360
61	PRISM/PRDM6, a Transcriptional Repressor That Promotes the Proliferative Gene Program in Smooth Muscle Cells. <i>Molecular and Cellular Biology</i> , 2006, 26, 2626-2636.	2.3	117